Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lombardo has to go now! What has he done since he has been hired? Nothing!
After reading all the messages today, I have some thoughts-
I think Dan wanted to go it alone for for maximum payday at the end. BOD was willing to go that route but something (perhaps a partnership or complete buyout of a particular indication that Dan didn't want to do) caused a irreconcilable difference between Dan and the BOD.
With Dan gone, fbg lost his reason for living.
In order to get a respectable CEO, isn't Advaxis going to have to pay more and give more shares than what they were paying and giving Dan?
I'm in for the long haul...just hope it's shorter now.
Just some thoughts while I'm watching USA vs. Canada softball.
Now, are there any Major League CEO's available to steer this ship? If it's true that the BOD forced him out, they better have had a replacement ready to go, otherwise, they should all resign.
Many of today's posts and reposted material have been very informative. Thanks to all who have shared all of this information!
That's ok. I think it was a rounding error on your part!
I shared Anita's video, as well as the throat cancer video on facebook. Everyone should share these videos on facebook.
After reading the long story on Dendreon, I have a couple thoughts. First, it's crazy that as a small investor, I would recognize a lot of those names and how lofty their reputations seem to be. I've always taught the kids that I coach in sports that it takes a lifetime to build a great reputation but just a second to destroy it. These people fly completely opposite to this, yet are held in high esteem! Secondly, longs could replace the Dendreon ticker with the Advaxis ticker-the story seems so similar in many ways. Here's hoping we don't have a similar outcome.
Missed the Kathy Ireland interview. Was it a new interview or a repeat of the last one?
We need to use our algorithms on the share price repression algorithms!
My thought on tomorrow (nobody asked for it-shame on you!) is that there will be no news that we on this board haven't heard before. I think that is to be expected. What isn't known is how many potential new investors will be informed of this amazing investment. That could be the initial trigger followed by new results that all longs expect in the near future. Just my two cents
Everyone should share the Kathy Ireland interview on facebook. Maybe we inspire our friends to invest in this worthy company.
The cup is broken with fbg
Just sold my 50 shares of BABA at 125.24 and used the proceeds to buy more ADXS at 7.98. I'm way, way, way too extended on ADXS but I can't walk by a bargain.
Funny how both adxs and ibb both peaked today at 10:45 then retreated. Just an observation.
How does Dan make any money if he doesn't sell.
Randy Too, So don't you think Dan should get credit when we have green momentum? Or should he only get chastised when we have red momentum?
Bought another 300 shares @ $8.61 with my IRS refund. Now, let's really go!
Low volume on stock; no volume on warrants.
I've noticed that I use the "seven words" a lot less since I've put fbg on ignore!
OMG! ADXS down .27. Fire Lombardo now!
It was news to me. It might be "olds" to you. I hadn't seen that info before. Thought it was relevant.
It's nice to see the buys by the other institutions, though!
It's funny how un-downbeat the message board is on a GREEN day!
Just saw this-
Fmr LLC Reduces Stake in Advaxis, Inc. (ADXS)
Posted by Chloe McGuire on Apr 17th, 2017
FMR LLC decreased its position in Advaxis, Inc. (NASDAQ:ADXS) by 0.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,102,885 shares of the biotechnology company’s stock after selling 27,700 shares during the period. FMR LLC owned 10.22% of Advaxis worth $29,377,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Koshinski Asset Management Inc. bought a new stake in Advaxis during the third quarter worth $156,000.
Fox Run Management L.L.C. bought a new stake in Advaxis during the third quarter worth $175,000.
Creative Planning increased its stake in Advaxis by 2.8% in the third quarter. Creative Planning now owns 30,100 shares of the biotechnology company’s stock worth $322,000 after buying an additional 820 shares during the last quarter.
SG Americas Securities LLC bought a new stake in Advaxis during the third quarter worth $418,000.
Finally, Tocqueville Asset Management L.P. increased its stake in Advaxis by 32.2% in the third quarter. Tocqueville Asset Management L.P. now owns 71,300 shares of the biotechnology company’s stock worth $762,000 after buying an additional 17,350 shares during the last quarter. 57.42% of the stock is currently owned by institutional investors and hedge funds.
Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)
Advaxis, Inc. (NASDAQ:ADXS) traded up 1.29% during midday trading on Friday, reaching $7.86. 463,780 shares of the company traded hands. The company’s market capitalization is $316.72 million. The stock’s 50 day moving average is $8.37 and its 200 day moving average is $8.83. Advaxis, Inc. has a one year low of $6.47 and a one year high of $16.30.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings results on Friday, March 10th. The biotechnology company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.09. The business earned $3.79 million during the quarter, compared to analysts’ expectations of $2.15 million. On average, equities analysts anticipate that Advaxis, Inc. will post ($1.81) earnings per share for the current year.
ADXS has been the topic of a number of research analyst reports. HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a research note on Monday, March 13th. Cantor Fitzgerald reiterated a “buy” rating and set a $19.00 target price on shares of Advaxis in a research report on Monday, February 27th. Five investment analysts have rated the stock with a buy rating, Advaxis currently has an average rating of “Buy” and an average price target of $24.00.
Thanks again for the info from a report by hovacre!
Rode AAPL from $80 a share pre 7 for 1 split to where it is today. Originally got in at $201 a share. Nobody was asking for the CEO's head when it lost 60% of it's market cap. Just chillin' here.
I have 29,000+ shares with an average cost of $15+ riding here. Not complaining other than what does Tom Ridge bring to the table. And it's gccarlin to you!
I'll take any amount of green any day!
Green today. Where are all the "fire Dan" poster people now?
People here have over invested in ADXS as a percentage of their investment portfolio- me included. If you feel that uncomfortable, get out and take your loss. I'm holding on and not complaining. Made my bed and am sleeping on it.
Nice find! Hopefully all the people who need help will find that the doors are now open. C'mon down!
They are also on the R&D Committee
Could the vote cause shorts to start covering thinking that an institution (or two or three) are putting the spurs to the BOD?
Vote returns out. Someone with 6 million votes didn't like some of the candidates. Other items had closer outcomes. I wonder if the BOD will take the close outcomes under advisement.
Looks like it is "100 share" day for Advaxis.
Study finds FDA outpaces European regulators in review times, approvals of new drugs
(Ref: The New England Journal of Medicine, Los Angeles Times, ABC News)
April 6th, 2017
By: Katie Bell
Results from an analysis published in the NEJM on Thursday showed that the FDA approved 170 new therapeutic agents between 2011 and 2015, compared with 144 by the European Medicines Agency (EMA). Moreover, during the same time period, regulatory reviews by the FDA were 60 days shorter on average than those by its European counterpart, with the study authors noting that the extent of the difference in total review times between the two agencies "is similar to, or perhaps even greater than, that observed in our previous analysis of new therapeutic agents that were approved between 2001 and 2010."
The authors pointed out that while the 21st Century Cures Act, which was signed into US law last December, includes numerous reforms aimed at streamlining FDA evaluations, the speed of the regulatory review process is directed by the Prescription Drug User Fee Act (PDUFA). They explained that with Congress due to consider the reauthorisation of the PDUFA before it expires this October, the current analysis was intended to inform anticipated discussions about the speed of the FDA's regulatory review process.
In the study, researchers identified all new therapeutic agents that had been approved by the FDA and EMA between 2011 and 2015, and classified them according to therapeutic area and orphan status. Investigators abstracted key regulatory dates and compared median total review times.
Results showed that while the FDA approved more agents, the therapeutic areas of the approvals were similar in the two agencies. However, the FDA approved 43.5 percent of applications for orphan drugs, compared with 25 percent for the EMA. Meanwhile, the median total review time was 306 days at the FDA and 383 days at the EMA. The study found that for therapeutic agents used to treat cancer and haematologic disease, total review times were shorter at the FDA than at the EMA, but not for other therapeutic areas or agents designated as orphan drugs. Among the 142 therapeutic agents that were approved by both agencies, the median total review time was 303 days and 369 days, respectively, for the FDA and EMA.
Richard Pazdur, director of the FDA's Oncology Center of Excellence, commented that "it's an urban myth" that the FDA is slower than other countries to clear promising treatments.
US President Donald Trump has pledged to speed up the approval of new drugs by the FDA, describing the current process as "slow and burdensome,"and he has also expressed plans to work to lower drug prices. Scott Gottlieb, Trump's nominee to head the FDA, recently said that if he is confirmed as commissioner, he will recuse himself for a year from FDA decisions on 20 or more companies in which he has held financial interest or worked as a consultant. More recently, Gottlieb faced questions at his confirmation hearing regarding his financial ties to medical companies.
hovacre, I want to thank you for giving us the information in your SA article. It was well written and easily comprehended. You should be in charge of Advaxis PR!
hovacre, Thanks for the nice SA article.